| A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, ... Nature medicine 25 (12), 1938-1947, 2019 | 398 | 2019 |
| Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells M Daher, R Basar, E Gokdemir, N Baran, N Uprety, AK Nunez Cortes, ... Blood, The Journal of the American Society of Hematology 137 (5), 624-636, 2021 | 177 | 2021 |
| Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes P Matre, J Velez, R Jacamo, Y Qi, X Su, T Cai, SM Chan, A Lodi, ... Oncotarget 7 (48), 79722, 2016 | 168 | 2016 |
| Molecular pathways: hypoxia-activated prodrugs in cancer therapy N Baran, M Konopleva Clinical Cancer Research 23 (10), 2382-2390, 2017 | 118 | 2017 |
| Clonal selection and therapy resistance in acute leukaemias: mathematical modelling explains different proliferation patterns at diagnosis and relapse T Stiehl, N Baran, AD Ho, A Marciniak-Czochra Journal of The Royal Society Interface 11 (94), 20140079, 2014 | 97 | 2014 |
| Cell division patterns in acute myeloid leukemia stem-like cells determine clinical course: a model to predict patient survival T Stiehl, N Baran, AD Ho, A Marciniak-Czochra Cancer research 75 (6), 940-949, 2015 | 88 | 2015 |
| Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated blood and cord blood–derived NK cells facilitates CAR-like responses against CD30+ malignancies LN Kerbauy, ND Marin, M Kaplan, PP Banerjee, MM Berrien-Elliott, ... Clinical Cancer Research 27 (13), 3744-3756, 2021 | 87 | 2021 |
| Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials TA Yap, N Daver, M Mahendra, J Zhang, C Kamiya-Matsuoka, ... Nature medicine 29 (1), 115-126, 2023 | 86 | 2023 |
| Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia L Stuani, M Sabatier, E Saland, G Cognet, N Poupin, C Bosc, FA Castelli, ... Journal of Experimental Medicine 218 (5), e20200924, 2021 | 73 | 2021 |
| Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia Q Zhang, B Riley-Gillis, L Han, Y Jia, A Lodi, H Zhang, S Ganesan, R Pan, ... Signal transduction and targeted therapy 7 (1), 51, 2022 | 69 | 2022 |
| BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment S Piya, H Mu, S Bhattacharya, PL Lorenzi, RE Davis, T McQueen, ... The Journal of clinical investigation 129 (5), 1878-1894, 2019 | 63 | 2019 |
| The rarity of ALDH+ cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients VT Hoang, EC Buss, W Wang, I Hoffmann, S Raffel, A Zepeda‐Moreno, ... International journal of cancer 137 (3), 525-536, 2015 | 53 | 2015 |
| Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition K Saito, Q Zhang, H Yang, K Yamatani, T Ai, V Ruvolo, N Baran, T Cai, ... Blood advances 5 (20), 4233-4255, 2021 | 41 | 2021 |
| Brasil da Costa, FH; Konopleva, M SB Panina, N Baran Kirienko, NV A mechanism for increased sensitivity of acute myeloid leukemia …, 2019 | 34 | 2019 |
| Utilizing synergistic potential of mitochondria-targeting drugs for leukemia therapy SB Panina, J Pei, N Baran, M Konopleva, NV Kirienko Frontiers in oncology 10, 435, 2020 | 32 | 2020 |
| A mechanism for increased sensitivity of acute myeloid leukemia to mitotoxic drugs SB Panina, N Baran, FH Brasil da Costa, M Konopleva, NV Kirienko Cell Death & Disease 10 (8), 617, 2019 | 32 | 2019 |
| TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation B George, H Kantarjian, N Baran, JD Krocker, A Rios International journal of molecular sciences 22 (19), 10782, 2021 | 31 | 2021 |
| Differences between healthy hematopoietic progenitors and leukemia cells with respect to CD44 mediated rolling versus adherence behavior on hyaluronic acid coated surfaces M Hanke, I Hoffmann, C Christophis, M Schubert, VT Hoang, ... Biomaterials 35 (5), 1411-1419, 2014 | 31 | 2014 |
| Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia N Baran, A Lodi, Y Dhungana, S Herbrich, M Collins, S Sweeney, ... Nature communications 13 (1), 2801, 2022 | 29 | 2022 |
| Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML S Herbrich, N Baran, T Cai, C Weng, MJL Aitken, SM Post, J Henderson, ... Journal for immunotherapy of cancer 9 (7), 2021 | 28 | 2021 |
Michael AndreeffUT MD Anderson Cancer CenterVerified email at mdanderson.org
